In vitro pre-vascularisation of tissue-engineered constructs: A co-culture perspective by Baldwin, Jeremy et al.
VASCULAR CELL
Baldwin et al. Vascular Cell 2014, 6:13
http://www.vascularcell.com/content/6/1/13REVIEW Open AccessIn vitro pre-vascularisation of tissue-engineered
constructs A co-culture perspective
Jeremy Baldwin1, Mélanie Antille2, Ulrich Bonda1,3, Elena M De-Juan-Pardo1, Kiarash Khosrotehrani4,5,
Saso Ivanovski6, Eugen Bogdan Petcu6 and Dietmar Werner Hutmacher1*Abstract
In vitro pre-vascularization is one of the main vascularization strategies in the tissue engineering field. Culturing cells
within a tissue-engineered construct (TEC) prior to implantation provides researchers with a greater degree of
control over the fate of the cells. However, balancing the diverse range of different cell culture parameters in vitro is
seldom easy and in most cases, especially in highly vascularized tissues, more than one cell type will reside within
the cell culture system. Culturing multiple cell types in the same construct presents its own unique challenges and
pitfalls. The following review examines endothelial-driven vascularization and evaluates the direct and indirect role
other cell types have in vessel and capillary formation. The article then analyses the different parameters researchers
can modulate in a co-culture system in order to design optimal tissue-engineered constructs to match desired
clinical applications.
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Researchers have two main options when vascularizing
tissue-engineered constructs: either implant the construct
in vivo whereby the host system and local microenviron-
ment largely guide vascularization and the organization of
cells, or culture the cells under controlled conditions in
order to develop a functioning vascular network in vitro
before implantation [1,2]. The latter strategy offers a
higher degree of control, as researchers are able to modu-
late and optimize parameters under controlled conditions
prior to implantation. In in vitro culture systems capil-
laries and vessels are formed de novo (vasculogenesis)
rather than from existing vasculature (angiogenesis). In
most tissue engineering constructs capillaries and ves-
sels are formed by endothelial or endothelial progenitor
cells (EPC) rather than by precursor cells, such as
angioblasts, as described in the traditional definition of
vasculogenesis. Moreover, in a majority of cases, other
non-endothelial cells will also be cultured within the
same tissue engineered construct depending on the tis-
sue of interest [3]. Endothelial cells are a key structural* Correspondence: dietmar.hutmacher@qut.edu.au
1Institute of Health and Biomedical Innovation, Queensland University of
Technology, Brisbane, QLD 4059, Australia
Full list of author information is available at the end of the article
© 2014 Baldwin et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.and functional component of blood vessels and capillaries,
and play a critical role in the revascularization of local site
defects in wound healing and repair, such as diabetic
ulcers, damaged cardiac tissue and bone regeneration
[4-7]. Numerous studies have shown that the addition
of endothelial cells to tissue-engineered constructs in-
creases vascularization and perfusion in both in vitro
and in vivo settings [8-11]. However, managing mul-
tiple cell types in the same system can be difficult.
What may be an optimal condition for one cell type
may be detrimental or lethal to another cell type. Re-
searchers need to find the right balance for each cell type,
whilst taking into consideration the intended structural
and functional purpose of the tissue-engineered construct.
The following article reviews the various parameters to
consider in an in vitro co-culture system with a particular
focus on vascularization.
Cell source
A key first decision in designing an in vitro co-culture
system is the selection of appropriate cell types.
Endothelial and precursor cells
Endothelial cells are present in most tissues within the
human body; however, their relative abundance andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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array study on the expression profiles of 53 endothelial
cells showed distinct tissue-specific expression patterns
in cells isolated from different blood vessels and micro-
vasculature in the body [13]. There are a wide variety of
different types of endothelial cells used in the literature.
Researchers seeking to model a particular biological sys-
tem or disease state may choose to isolate them directly
from the tissue of interest. The logic behind isolating
cells from the tissue of interest is that the researchers
will be able to isolate endothelial subpopulations specific
to the microenvironment that they wish to recapitulate.
However, from a tissue engineering perspective, isolating
tissue-specific endothelial cells may not be a feasible
strategy as retrieving these cells may require an invasive
procedure, and in the case of major organs or tissues
may not be a viable option. In order for a specific cell-
based tissue engineering approach to be practical in a clin-
ical setting, the source of cells needs to be (i) relatively
abundant, (ii) readily available and (iii) pose a minimal to
low risk to patient/donors. Examples of non-invasive cell
sources include placental or umbilical cords which are
commonly discarded as medical waste, and examples of
minimally invasive procedures for isolation of endothelial
cells include peripheral blood and skin biopsy [14-16].
It is important to remember that isolated primary cells
are heterogeneous and contain a mix of different endo-
thelial cell subpopulations. In 2004 Ingram et al. identi-
fied a novel cell hierarchy among endothelial cells found
in human peripheral and umbilical cord blood based on
clonogenic and proliferative potential [17]. The endo-
thelial lineage is believed to follow a similar hierarchical
as myeloid and lymphoid lineages in which a primitive
stem cell gives rise to proliferating progenitor cells,
followed by the progression to terminally differentiated
cells [17]. Figure 1 shows the model of endothelial cell
hierarchy based on proliferative and clonogenic potential,
thus defining endothelial progenitors (EPC) as cells givingLPP-ECFC Mature 
Endothelial cells
Endothelial 
cell cluster
HPP-ECFC
Figure 1 Overview of endothelial cell hierarchy. High
proliferative potential- endothelial colony forming cells (HPP-ECFC)
give rise to all other subsequent endothelial progenitor cells, can
achieve greater than 100 population doublings and can form
secondary and tertiary colonies upon replating. Low proliferative
potential –endothelial colony forming cells (LPP-ECFC) can give rise
to colonies containing more than 50 cells, whilst endothelial cell
clusters give rise to colonies with fewer than 50 cells. Neither
LPP-ECFC or endothelial clusters can give rise to secondary or
tertiary colonies. Mature endothelial cells are terminally differentiated
and have a limited proliferative potential [17].rise to high proliferative colonies with the capacity to form
blood vessels upon transplantation. A further study identi-
fied a subpopulation of endothelial progenitor cells (EPC)
within human umbilical vein endothelial cells (HUVEC)
and human aortic endothelial cells (HAEC) [18]. Both
HUVEC and HAEC can be isolated from vessel walls and
were previously thought to consist of only mature dif-
ferentiated endothelial cells [19]. The heterogeneous
composition of isolated endothelial cells may affect the
reproducibility of cell-based treatments and isolated cells
may need to be sorted into individual cell populations.
The therapeutic potential of EPC subpopulations of
endothelial cells has garnered a significant amount of
interest within the research community in recent years.
EPCs have been shown to have enhanced proliferative
potential, are able to differentiate and give rise to all sub-
sets of the endothelial cell lineage and have been shown to
improve vasculogenic activity [20]. Other studies have also
shown that EPC have a higher survival rate in vitro in
comparison to HUVEC [21]. Despite these facts, re-
searchers have experienced mixed and sometimes conflict-
ing results when trying to translate EPCs in a preclinical
and clinical setting [22]. A potential source of this discrep-
ancy may lie in the lack of a unified definition of an EPC
and an understanding of mechanisms that underline the
cells therapeutic mode of action. Much of the controversy
stems from the diverse range of cell isolation techniques
and cell markers that have been historically used to
identify and characterize EPCs [23]. The three main
types of EPCs in literature, as classified by their isolation
from peripheral blood – mononuclear cells (PB-MNC), in-
clude culture of colony forming unit Hill (CFU)-Hill cells,
circulating angiogenic cells (CAC) and endothelial colony
forming cells (ECFC) [24-26].
CFU-Hill are non-adherent PB-MNC that give rise to
colonies after 5 days following depletion of adherent
cells on fibronectin and CAC cells are adherent PB-
MNC that attach to fibronectin or gelatin surface after
4–6 days of culture [24,25]. Both CFU-Hill and CAC
cells co-express CD31, VEGFR-2 and CD133 [27]. CD133
is a hematopoietic stem cell (HSC) marker that is lost as
cell differentiate [28]. Peichev et al. hypothesized that
CD133 may also be a marker for immature EPC popula-
tions [29]. A later study by Case et al. in 2007 however
showed that 99% of CD34+ VEGFR-2+ CD133+ cells also
co-expressed CD45+, a common leukocyte antigen, not
expressed by endothelial cells [30]. In addition CD34+
VEGFR-2+ CD133+ cells also readily ingest bacteria and
lacked the ability to form human vessels de novo in vivo
[22]. Hirschi et al. proposed that the isolation strategies
for CFU-Hill and CAC cells may actually enrich for
monocyte/macrophage committed cells rather than EPCs,
but that these cell types can mimic an endothelial pheno-
type under angiogenic conditions [27]. These findings
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macrophage/monocyte phenotype and do not full commit
to endothelial cell fate, if for example the angiogenic
stimulus is removed or the cells are presented with an in-
flammatory or foreign body response, common at surgical/
injury sites, will the cells revert to their previous macro-
phage state [27].
ECFC on the other hand are late outgrowth cells that
form colonies on type 1 rat tail collagen following 14–21
days of culture [26]. According to Ingram et al. ECFC
more closely match the criteria of being a true EPC [17].
Unlike CFU-Hill and CAC cells, ECFCs do not express
haemopoetic markers such as CD133 and CD45 [31].
ECFC are highly proliferative and have the potential to
form both secondary and tertiary colonies on replating
[17]. ECFC are also capable of forming human vessels de
novo in vivo and incorporating into existing vascular
networks created by the co-culture of mature endothelial
and fibroblast cells [32].
The findings from these studies highlight the striking
differences between the different classes of putative EPCs
and have important implication for their therapeutic appli-
cation. Although CD34+ VEGFR-2+ CD133+ cells cannot
initiate vessel formation de novo in vivo, the cells can still
contribute to neoangiogenesis. For example, the putative
EPCs, in contrast to late outgrowth ECFCs, are able to
support existing vasculature through the secretion of an-
giogenic factors [32]. CD34+ VEGFR-2+ CD133+ cells can
hone to and transiently adhere to vasculature surfaces that
lack an endothelial lining [27,29]. The endothelial covering
is critical in normal blood vessel and capillary function.
The ability of the putative EPCs to mimic endothelial
phenotype suggests the cells support damaged or devel-
oping vessels by providing a temporary substitute endo-
thelium until it can be replaced by endothelial cells [27].
Further research is needed to fully characterize each
EPC cell type and their mode of action in order to de-
velop more targeted strategies for each cell type in tis-
sue engineering.
Another major limitation of ECFCs is their rarity
within the human body. EPC only make up 0.01% of cir-
culating mononuclear cells in peripheral blood [33]. An
alternative source of ECFC is umbilical cord blood or
placental tissue. The number of endothelial cell colonies
derived from umbilical cord blood was 15 times higher
than from equivalent volumes (20 mL) of peripheral
blood [17]. The colonies formed by umbilical cord blood
were also consistently larger than those isolated from per-
ipheral blood [17]. More recently, it has now become pos-
sible to also isolate ECFCs from the placenta tissue. From
a single placenta (500-600 g) it is possible to isolated the
same amount of ECFCs as found in 27 whole cord blood
(60 mL) samples [34]. Gene expression and functional
studies have demonstrated that these cells are equivalentto umbilical cord blood derived ECFCs [34]. The high
number of ECFCs that can be derived from these tissues,
that are commonly discarded, is opening new possibilities
in tissue engineering, in particular in large defect applica-
tions that require high cell numbers.
An alternative strategy may be to expand isolated
ECFC ex vivo, however only a limited number of studies
have explored the effects that ongoing cell culture may
have on ECFCs. Endothelial progenitor cells at a single
cell level can be expanded 10,000-fold and from a single
cord blood sample it is possible to obtain greater than
109 progeny [17,18]. However these expanded cells may
not necessarily all be progenitor cells. A common prob-
lem with ex vivo expansion of progenitor cells is that
mature cells rather than immature cells are expanded
[35]. Therefore ECFC cells in culture may develop into a
mixed population of endothelial cells. A study by Corselli
et al. also observed a progressive differentiation of ECFC
into more mature endothelial cells over time in culture
based on decrease in proliferative potential, reduction of
CD34 expression and improved tube formation capacity
[36]. Moreover, the same study found that large scale
ex vivo expansion of endothelial progenitor cells can also
result in a high incidence of cytogenetic alteration [36].
Interestingly, this phenomena was only observed in um-
bilical cord derived EPCs, but not in blood-derived
EPCs. Although no tumorgenicity was observed by
the cells in vivo, it does raise important health and
safety concerns for use of expanded endothelial pro-
genitor cells in clinical applications. Further research
is required to determine the optimal conditions to ef-
fectively expand ECFC whilst conserving progenitor
expression and phenotype.
Mature endothelial cells and endothelial cell clusters
lack the ability to be expanded out into high numbers
like their ECFC counterparts, however these endothelial
cells are still capable of forming capillary-like structures.
ECFC cells are responsive to angiogenic factors, have a
high survival rate and are believed to play a key role in
maintaining vessel wall integrity [18,19]. Therefore the use
of mature endothelial cells/endothelial cluster subpopula-
tions to form an in vitro capillary network without pro-
genitor endothelial cells, such as ECFCs, potentially draws
into question the long-term stability of the newly formed
vascular network. However this issue may be overcome
later after implantation when the vascular network is inte-
grated and reperfused by the host system, which may
allow the construct to be repopulated by circulating
ECFCs in adult peripheral blood.
Multipotent adult stem cells
Adult stem cells are multipotent cells that are capable of
differentiating into a narrow range of different cell types
[37]. Recent advances in our understanding of stem cell
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range of novel tools and research strategies to guide cell
fate both within and outside their traditional cell line-
ages. Bone marrow mesenchymal stem cells (BM-MSC)
have been shown to readily differentiate into endothelial
cells under angiogenic conditions. Differentiated BM-MSC
express several endothelial markers in vitro including,
vWF, VEGFR1/2 (FLT-1/KDR) and VE-cadherin [38]. BM-
MSC formed vessels in vivo which were fully perfused as
demonstrated by the presence of erythrocytes in the vessel
lumen [39]. Adipose derived stem cells are also capable of
differentiating into endothelial cells following stiumulus by
VEGF and FGF-2 [40]. These cells are positive for CD31,
CD34, VE-cadherin and endothelial cell nitric oxide syn-
thase (eNOS). The cells are also capable of forming cord-
like structures in vitro on matrigel, and when injected into
an ischemic hindlimb mouse model formed vessels within
the mouse vasculature and markedly improved blood flow
within the ischemic hindlinmb. It is also possible now to
isolate multipotent stem cells from urine. Urine-derived
stem cells (USC) are isolated from voided urine or urine
from the upper urinary tract [41]. USCs have high prolifer-
ative potential and can be expanded up to 50 population
doublings [42]. USC can be differentiated into endothelial
cells following supplementation of VEGF in media. Endo-
thelial differentiated USC have been shown to be capable
of forming tubular structures in vitro on matrigel and ex-
press several endothelial specific markers, including vWF,
CD31, KDR/FLT-1, eNOS and VE-cadherin [43]. The ad-
vantage of multipotent adult stem cells from a tissue en-
gineering perspective is that these cell types can be
isolated from non-invasive (eg. urine) and minimally in-
vasive (eg. bone marrow; fat tissue) sources. Also unlike
induced pluripotent stem cells (iPS) and embryonic
stem cells (ESC), they are less likely to form teratomas
in vivo.
Pluripotent stem cells
In the past ten years there has been significant advance-
ment in the fields of stem cell biology and iPS technol-
ogy [44]. These developments have had a tremendous
impact on regenerative medicine and tissue engineering
concepts. Unlike endothelial progenitor cells, pluripotent
stem cells have the potential of differentiating into all
three germ layers [45]. The most recognizable and well
characterized pluripotent cells are ESCs. A number of
studies have been able to differentiate ESC into endothelial
and associated mural cells [46,47]. ESC-derived endothe-
lial cells were shown to contribute to the construction of
new blood vessels and improved blood flow in a hindlimb
ischemia model [48]. However ethical concerns surround-
ing the isolation of ESC limit the widespread application
and adoption of this cell technology [49]. Other technical
limitations associated with the use of ESC include sourceavailability, difficulty in separating out endothelial cells
from undifferentiated ESC cell and the potential for ESC
to form teratomas [49-51].
iPS cells are differentiated cells that have been genet-
ically reprogrammed to return to a pluripotent stem cell
state and therefore circumvent the need to source cells
from embryos [52]. A large body of research from the
mid 1990s to early 2000s identified a number of key
genes relating to maintenance and regulation of pluri-
potency in embryos and ESC [53-58]. In 2006 a seminal
paper by Dr Shinya Yamanaka’s laboratory at Kyoto Uni-
versity screened 24 of these genes as candidates for in-
ducing pluripotency in somatic cells and identified four
factors, including Oct3/4, Sox2, c-Myc and Klf4, that
were able to successfully produce iPS cells from mouse
adult fibroblast cells [59]. Since this study, a number of
laboratories have been able to use Dr. Yamanaka’s tech-
nique to generate iPS cells from a variety of different
cell types and species including humans [60]. Once the
cells have returned to a pluripotent state the cells can
then be re-differentiated into endothelial and associated
mural cells. Choi et al. were able to differentiate seven
human iPS cell lines into endothelial (CD31+, CD34-)
cells [61]. The iPS-derived endothelial cells were shown
to successfully form capillary-like structures on growth
factor reduced matrigel in 2D. Another study by Samuel
et al. was able to establish functional blood vessels
long-term (280 days) in vivo using endothelial cells
and perivascular MSCs from the same human iPS cell
line [62]. The study was also able to replicate the re-
sults using human iPS cells from patients with type 1
diabetes that are predisposed to vascular complica-
tions. A particular limitation of iPS cells is that they
still may maintain their epigenetic memory (i.e. DNA
methylation and histone modification) and prevent the
cells from fully recapitulating ESC cells [63]. Several of
the iPS cell genes are also oncogenes, and like ESCs,
these cells are also capable of forming teratomas
in vivo [64].
Pluripotent stem cells represent a potential universal
cell source for endothelial cells, but the technology is
still in the early stages of development and if researchers
cannot rectify the issues associated with the cells, in
particular the safety concerns, the technology will never
be able to move beyond pre-clinical applications into
clinical regenerative therapies.Supporting cells
Cells that are grown in conjunction with endothelial
cells can have both a direct and indirect impact on the
development of vascular networks in tissue-engineered
constructs. Figure 2 highlights the role that these cells
can have on capillary formation and maturation.
Endothelial Cell Type Growth Factors/Cytokines
(B) Direct (A) Indirect
Figure 2 Overview of the roles of supporting cells in capillary formation. (A) Indirect role of supporting cells in establishment and
maintenance of capillary structures through release of cytokines and growth factors and (B) direct role of supporting cells in the structural and
functional support of blood vessels and capillaries.
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Cells are dynamic systems and the cross-talk between
different cell types through cell signaling, growth factors
and cytokines can have a profound effect on cell morph-
ology, behavior and gene expression. In monoculture,
endothelial cells will not form into tubes and will remain
rounded unless the culture media is supplemented with
angiogenic factors. It is interesting to note however that
when endothelial cells are co-cultured with other cell
types, such as fibroblasts and osteoblasts, the cells are
able to form capillary like structures without the need
for exogenous stimulus [65-68]. These supporting cells
constitutively express angiogenic factors, such as vascu-
lar endothelial growth factor (VEGF), basic fibroblast
growth factor (bFGF) and angiopoietin-1 (Ang-1), which
can regulate endothelial tube formation through a local
paracrine effect (Additional file 1: Table S1). For example,
VEGF is expressed by human osteoblast (hOB) monocul-
tures, but is not detectable in human dermal microvascu-
lar endothelial cell (HDMEC) monocultures [69]. When
HDMEC and hOB cells were co-cultured together on a
polycaprolactone-starch scaffold, capillaries formed after
28 days, and the levels of VEGF were 2–4 times higher
than comparable hOB monocultures [69]. Data showed
that VEGF expression may be enhanced via a positive
feedback mechanism between the cells, whereby VEGF re-
leased by osteoblasts triggered the release of prostaglan-
dins from the HDMEC cells through a cyclooxygenase-2
(COX-2) dependent pathway which in turn up regulated
VEGF secretion from osteoblasts.
However, not all cell types play a supportive role in vas-
cular formation. Human microvascular endothelial cells
are capable of forming capillary-like networks in 3D fibrin
and collagen gels under angiogenic conditions, but the
addition of chondrocytes or chondrocyte conditioned
media has been shown to prevent tube formation [70].
This is because chondrocytes express TGF-β1, which
can inhibit EGF/TGF-α dependent capillary formation
in vitro [71]. Moreover, HUVEC co-cultured with fibro-
blasts had a pro-angiogenic effect on the cells, but the
addition of limbal epithelial cells into the system had astrong inhibitory effect on the fibroblast induced tube
formation [72]. Both cartilage and epithelium (i.e. cornea)
are avascular tissues, whilst fibroblasts and osteoblasts are
generally located in vascularized tissues [73], and dis-
crepancies in the effect that these cells have on endothe-
lial cell capillary formation may be a part of physiological
programming.
Direct supporting cells
Other cells provide direct support to endothelial cells.
These perivascular cells, or mural cells, help stabilize
and maintain capillary formation [74]. Several studies
have reported the ability to induce endothelial cell tube
formation in vitro, only to have these newly established
capillary networks regress and collapse within weeks
or even days [75,76]. It is hypothesized that the same
factors that promote tube formation can also lead to
vascular network regression. The addition of pericytes has
been reported to stabilize newly developed endothelial
tubes by regulating proteinase through the release of in-
hibitors, such as tissue inhibitor of metalloproteinase 2
and 3(TIMP-2/3) [77]. Pericytes have also been shown to
induce endothelial cells to synthesize and deposit base-
ment membrane proteins, such as laminin, collagen IV,
perlecan and fibronectin, which have been shown to
stabilize capillaries and vessels [78]. Mesenchymal stem
cells (MSC) have also been shown to provide structural
support for neovessel formation. Co-culture of MSCs with
either EPC or HUVEC cells has been shown to induce
MSC to differentiate into mural cells by enhancing alpha
smooth muscle actin(α-SMA) expression [79]. The effect
requires direct cell-cell contact between endothelial cells
and works via an extracellular signal regulated kinase
(ERK)-dependent pathway. Blood vessels engineered from
HUVEC and MSC have also been shown to respond to
vasoconstrictive stimuli, such as endothelin-1 [80].
Assays for the functional assessment of vascularization
A number of in vitro and in vivo assays are available for
assessing capillary formation in tissue engineering con-
structs. The foremost test for evaluating vascularization
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culture systems vessel formation can be visualized using
endothelial specific-markers, such as CD31 or vWF, or
by pre-labeling the cells prior to culture. Capillary struc-
tures can be reconstructed in 3D by stitching together
single image stills. Skeletonization of networks enables
further analysis of morphometric parameters such as
vessel volume, branching points, vascular orientation,
average segment length and diameter [81]. Lumen for-
mation is a critical step in the functionalization and mat-
uration of a capillary networks. Lumen formation can be
detected in a variety of different ways. Gel properties can
be exploited to directly identify lumens. For example, lu-
mens can be detected in endothelial cells embedded in
collagen gels by staining using collagen antibodies. If the
inside of the capillary do not stain for collagen, this indi-
cates that a hollow lumen has formed [82]. A limitation of
this approach is that it is dependent on the availability of
antibodies specific to the gel of interest. Lumens can also
be indirectly detected by staining for basement membrane
deposition and other proteins associated with vacuole for-
mation. Another important marker of vessel functionality
is selective permeability. Grainger and Putnam developed
a model of inverse permeability in which gels are placed in
a solution of fluorescently labelled dextran to allow free
diffusion for 30 minutes [83]. If the capillaries are mature
with competent cell-cell junctions the labeled dextran will
not be able to penetrate the inner hollow lumen; if the la-
beled dextran is detected within the lumen than the tight
junctions are incomplete and the capillaries are immature.
Although in vitro assays can assess the vascularization
potential of a tissue engineered construct, only in vivo
evaluation can demonstrate if capillary structures formed
in vitro can survive in a host system and integrate with
the host vasculature. In animal models, labeling the
cells prior to implantation or in the case of xenograft
models the use of species-specific antibodies can be
used later during analysis to distinguish between the
contributions of donor and host cells in explanted tissue
engineered constructs. The detection of erythrocytes in
the lumen structures of the vessels following for example
a hematoxylin and eosin (H&E) stain can indicate success-
ful reperfusion via anastomosis with host vasculature. A
more concise assay for assessing vessel perfusion in vivo is
through the intravenous injection of labeled lectin into the
animals prior to sacrifice [84]. Lectin binds the endothe-
lium of blood vessels [85]. If the vessels have indeed con-
nected to the host circulatory system the labeled lectin
can be detected when processing the samples downstream
and scanning for the relevant fluorescence. Another assay
for evaluating vessel perfusion is through the injection
of radio-contrast agents, such as Microfil and Angiofil,
prior to sacrifice or post-mortem [86,87]. Similar to the
lectin assay, the radio-contrast agent is injected intohost vasculature system, but instead of staining the
compound polymerizes to form a 3D dimension cast of
the circulatory system. Functional vessels in the con-
struct can be visualized in 3D using micro-CT. A disad-
vantage of this technique is that the radio-contrast
agents cannot distinguish between host and donor cells.
Advancement in whole mouse imaging systems coupled
with cell labeling can assist in tracking cell fate without
having to sacrifice the animal [88]. This enables real-
time monitoring of cells post-implantation and different
cell labels can distinguish between multiple cell types. A
limitation of this approach is the presence of autofluo-
rescence from innate biological molecules in some tis-
sues, such as skin or fur, which can interfere with
labeled cell signals. However, this problem may be over-
come using appropriate imaging filters or switching to a
bioluminescene encoding protein [89].
Co-culture parameters
There are a number of parameters that require careful
consideration when designing a co-culture system. Some
conditions may be considered trivial, but can have import-
ant implications for the end tissue-engineered product.
Scaffold/Matrix selection
In tissue engineering, scaffolds and matrices provide
cells with support and structure to move from 2D tissue
culture plate into a 3D microenvironment. The three
main types of 3D scaffolds include; solid scaffolds,
hydrogels (Figure 3A-B) or a combination of the two
constructs (Figure 3C). Solid scaffolds are porous 3D
structures, whilst gels are polymer networks that are ex-
panded throughout their volume by fluid. Thus far, only
hydrogels have been shown to form functional vascular
networks with lumen in vitro. The main difference be-
tween the two constructs is that in hydrogels cells are
completely embedded and are able to rearrange them-
selves in 3D, whilst in scaffolds, despite the fact that the
constructs are 3D in nature, the cells are seeded on the
scaffold surface and are in this sense on a 2D plane. The
complete immersion of cells in a 3D environment is crit-
ical in order to allow the cells to self-assemble and
organize into functional capillary networks. In 2D endo-
thelial cells can form cord-like structures; however, it is
only in 3D that endothelial cells are capable of forming
functioning lumens [90]. Lumens are the empty space
inside capillaries and vessels in which blood flows, and
therefore their development is critical in the effective re-
perfusion of tissue engineering constructs upon implant-
ation [75]. The only exception may be if the cells on the
scaffold secrete enough ECM in order to completely en-
capsulate the endothelial cells.
However, it is important to note the immersion of cells
in a 3D environment by itself also will not lead to
(A) (B) (C) (D)
(E) (F) (G)
Figure 3 Overview of tissue engineering constructs. Endothelial cells encapsulated within a (A) hydrogel and (B) seeded on a solid scaffold.
Only functional capillaries with lumen form in hydrogels. (C) Hybrid construct combining the tube forming capabilities of the hydrogel with the
structural support of a scaffold. (D) Photolithography used to etch microchannels into a silicon master mold. Biomaterial cast into mold to create
a patterned surface. Patterned layer bonded to flat unpatterned surface to create closed system. Multiple layers can be fused together to create
larger 3D constructs. (E) Biodegradable material dissolves in biomaterial to leave patterned microchannels. (F) Whole tissue organs decellularized
leaving the ECM intact with a hollow vasculature network that can later be re-seeded with endothelial cells. (G) Cell sheeting engineering used
to create vascularized 3D constructs by sandwiching endothelial cell sheets with non-endothelial cell sheets together.
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and degradable sites throughout the matrix in order to move
freely and organize themselves into 3D structures [91]. Na-
tive ECM derived materials, such as collagen and fibrin gel,
naturally have binding and cleavable sites for cells, whereas
synthetic gels may require the incorporation of additional
peptide sequences, such as RGD (Arg-Gly-Asp) binding and
matrix metalloproteinase (MMP)-degradable sites [91].
The mechanical properties of a construct can also play
an important role in capillary formation. In literature the
range of stiffness as measured by compression modulus
for optimal tube formation in hydrogels varies between
different gel types, however in all cases increased vascu-
lature formation was associated with decreasing stiffness
[92-95]. The phenotypic expression of other cell types
on the other hand can increase with increasing stiffness.
For example, in bone tissue engineering, stiffer gels can
increase bone mineralization and expression of differen-
tiation markers such as osteocalcin, osteopontin and
alkaline phosphatase [96,97]. The selection of optimal
construct stiffness can be problematic if attributes (i.e.
vascularisation and bone formation) are desired in the
same construct, but inversely related. Researchers need
to find a middle ground or alter another parameter in
the system.
Fabrication of microchannels
A new wave of vascular constructs and designs are help-
ing to speed up the tube formation process and assist
with co-culture strategies. The process of capillary for-
mation in vitro follows four main steps (i) cell elongation
and cell-cell interaction, (ii) development of nascentendothelial tubular network, (iii) lumen formation and
(iv) capillary stabilization and maturation [98]. Cell-driven
tubulogenesis and lumen formation involves a complex
set of cell-cell interactions and biological mechanisms
[90]. In latent hydrogels this process can takes time, and
produces networks that are often not uniform and can
regress after a few days of culture. A new approach re-
searchers are now taking is to pre-fabricate hollow
microchannels and to seed endothelial cells within these
constructs. This approach helps researchers to skip the
initial stages of capillary formation by helping to localize
the endothelial cells in these channels and provide a tem-
plate for network development. Another benefit of this
strategy from a co-culture perspective is that it enables
researchers to compartmentalize different cell types.
For example, endothelial cells can be perfused through-
out the channels, whilst other cell types can be seeded
in the surrounding biomaterial [99]. Microchannels can
be fabricated using current microfabrication techniques
or be naturally derived by using existing vascular net-
works and structures from decellularized whole organ
and tissues.
Concepts from microfluidics can be utilized to engineer
vasculature for tissue engineering. Microfabrication tech-
niques, such as photolithography, can be used to etch mi-
cron sized open channels into a silicon master mould
(Figure 3D) [100]. A polymer of interest can then be
poured into the mould in order to create a patterned sur-
face. Once set the patterned layer can be removed and
then bonded with a flat unpatterned layer of polymer to
create a closed system. Different polymer layers can be fused
using plasma treatment, temperature/pressure difference, or
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structs can then be further stacked and bonded to create lar-
ger 3D tissue engineered constructs. A major limitation of
the layer bonding technique is the danger of leaks if the
layers are not completely fused together.
Another microfluidic approach is to mould a biodegrad-
able material into the shape of a vasculature network and
then embed the construct within a biomaterial of interest
(Figure 3E). The construct acts as a sacrificial material that
degrades over time to leave hollow microchannels behind.
This method can also be combined with additive manufac-
turing techniques to create complex 3D vasculature struc-
tures [101]. Another benefit of biodegradable microfluidic
channels is that unlike the layer bonding method the sur-
rounding biomaterial formed is intact and there is a lower
danger of leaks forming, however the drawback is that the
technique doesn’t have the high resolution of other micro-
fabrication techniques such as photolithography.
A final approach is to re-endothelialise decellularized
whole tissue or organs using the existing vessel structures
as templates (Figure 3F). Advances in decellularization
processes in recent years have now made it possible to re-
move cells from tissue whilst retain the vital structure and
bioactivity of the ECM [102]. The organs and tissue can
also be sourced from xenogenic tissues which are readily
available. A limitation of this approach is that users are re-
stricted to the layout of vascular structures in the tissue.
There are also still unresolved concerns surrounding the
antiginicity, immunogenicity and shelf life of decellular-
ized organs [103].
Cell sheet technology
A final technique for developing tissue engineered con-
structs is cell sheet technology (Figure 3G). Cell sheet
engineering is a non-scaffold based approach that uses
temperature responsive cell culture surfaces to harvest
intact cell sheets that can be stacked together to recon-
structs 3D tissue [104]. The temperature responsive cul-
ture surfaces are created by treating normal tissue
culture plates with poly(N-isoproplyacrylamide)(PIPAAm)
that can alternate between states of hydrophobicity and
hydrophilicity [105]. At temperatures higher than 32
degrees the substrate is hydrophobic and cells can attach
to the surface and form a confluent layer. Lowering the
temperature below 32 degrees causes the substrate to be-
come hydrophilic and the cells sheet and ECM to detach
from the surface. A gel coated plunger can then be used to
manipulate and stack the cell sheets. The cell sheet tech-
nique has been used to effectively replicate tissue and or-
gans, such as skin and cardiac tissue, both in vitro and
in vivo [106,107]. A recent study by Asakawa et al. was
able to pre-vascularise a cell sheet construct in vitro by in-
corporating layers of endothelial cells [108]. The formation
of tubular structures with hollow lumen was observed inthe 3D cell sheet tissue after 7 days. A limitation of this
approach is that the cell sheets are fragile and can be diffi-
cult to handle [109]. Fabrication of cell sheet constructs
have also thus far been limited to tissue no thicker than
100-200 μm [109].
Cell ratio
The ratio between the different cell types in co-culture
can influence cell characteristics, behavior and survival.
In view of the available literature, no consensus exists on
the optimal cell ratio of endothelial cells to tissue-specific
cells for use in in vitro co-culture studies. The choice of
ratio will depend on factors such as cell viability and
desired expression of phenotype within the co-culture
system. Some groups use a high ratio of endothelial
cells as the endothelial cells will not form capillary
structures or survive long term at low ratio within the
particular systems [68,110]. Others groups favor a
higher non-endothelial cell ratio in order to push the
tissue engineered construct towards a particular pheno-
type [111,112]. For example Xing et al. seeded low ratio
(1:5 and 1:2) of HUVECs with hOBs to increase osteogenic
marker expression [111]. The expression of osteogenic
markers, such as alkaline phosphatase and insulin-like
growth factor-1 (IGF-1), increased with increasing ra-
tio of osteoblasts, however in all condition the endothelial
cells still formed capillary like structures. In a majority of
other studies researchers selected only a 1:1 cell ratio, how-
ever this may just be for the purposes of simplicity rather
than a specific cell benefit [113,114].
A key characteristics to consider when selecting the
ratio of cells to use in a co-culture system is the cells in-
dividual metabolic and proliferative potential. If the cells
proliferative and metabolic activity differs significantly,
depending on the duration of in vitro culture the more
active cells could overgrow the culture or starve the
other cell type, respectively. The best way to optimize
the cell ratio is via experimentation. Proliferation studies
can easily be conducted in monoculture in 2D or 3D
followed by analysis using commercial assays, such as
Alamar blue and MTT that measure metabolic activity
or CyQuant and PicoGreen that measure DNA content
[115]. However this approach may not be sufficient be-
cause it does not take into account the presence of the
other cell type and the effect that it may have on the
cells proliferation and activity. A better approach is to
perform the proliferative studies in co-culture using vari-
ous ratios of each cell type. The difficulty in this method
is to find a way to distinguish between the cell types.
The proliferation assays mentioned previously measure
total DNA content or metabolic activity in the system
and do not discern between different cell types. This
limitation however may be overcome by pre-labeling the
cells or staining for cell-specific markers. Labeled cells
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scope or by detaching the cells and processing them via
flow cytometry [116]. Flow cytometry and immunostain-
ing can also be used to assess cell expression and main-
tenance of phenotype at the various cell ratios during
ongoing in vitro culture.
Culture medium
The composition of culture media is one of the key points
to consider when culturing cells in vitro. Cell culture
medium consists of a complex mixture of amino acids,
vitamins, salts, supplements and/or serum that has been
individually optimized for each cell type. Common basal
medias for endothelial cells include EBM-2, M199,
M207 Ham’s F12K and MCDB −131. Endothelial cells
are also highly dependent on media supplements for
proliferation and maintenance of cell morphology and
phenotype. A traditional approach to culturing endo-
thelial cell was to supplement the media with endothe-
lial growth cell supplement (ECGS) and heparin [117].
ECGS is a crude extract from bovine neural tissue
which has been shown to have a potent mitogenic effect
on endothelial cells of mammalian origin. The main
component of ECGS is FGF which binds with heparin
to promote ligand formation with FGFR receptor on
endothelial cells to promote cell growth. A limitation of
ECGS supplementation is that the product has variable
composition and is animal derived. As our knowledge
and understanding of endothelial cells has expanded,
researchers have developed a greater understanding of
the factors important in endothelial growth and devel-
opment and as a result more chemically defined medias
have been developed. Examples of common media sup-
plements include VEGF, EGF, FGF, IGF-1, ascorbic acid,
hydrocortisone and SDF-1. However several studies have
shown that different endothelial cell types (microvascular
vs. macrovascular or mature vs. progenitor endothelial
cells) respond differently to various growth factors and
cytokines [118-122]. Therefore the selection of accom-
panying supplements is highly dependent on cell source
and location.
The use of serum is another important consideration
in endothelial cell culture. Serum is a common media
additive to support cell growth and viability in vitro,
however its composition is undefined and its use to ex-
pand cells for tissue engineering application has been
linked to immune response in patients and prion trans-
mission [123-125]. Several commercially available me-
dias have been developed that substitute serum with
increased growth factors and hormones, such as Human
endothelial –SFM. These serum free media have been
shown to support long-term culture of mature endothe-
lial cells, such as HUAEC, HUVECs and HMVECs, but
regardless of the growth factor combination do notsupport ECFC outgrowth without serum [126,127]. This
data suggests that other factors in the serum outside
growth factors may play an important role in ECFC ex-
pansion. Harvey et al. examined the serum factors in-
volved in endothelial cell morphogenesis by depleting
lipids from serum with activated charcoal [128]. The
ability of endothelial cells to form capillaries on matrigel
was significantly reduced in media with charcoal-treated
serum, however this function was restored following the
addition of the lipid sphingosine 1-phosphate. It is hy-
pothesized that the lipids work in synergy with protein
growth factors to promote capillary formation and the
addition of these factors may improve serum free media
strategies. Another alternative strategy is to use human
blood products rather than fetal or bovine derived serum.
Human blood plasma or platelet lysate have been able to
successfully expand ECFC ex vivo [127,129,130]. Indeed,
ECFC cells expanded using humanized cell media main-
tained their progenitor cell hierarchy, high proliferative
potential, endothelial cell markers expression and were
capable of forming capillary tubes on matrigel.
In a co-culture scenario each cell will have its own in-
dividual media requirements. In some cases the cells
may utilise the same media, but often this will not be
the case. If cells require different culture media, re-
searchers need to optimize an appropriate media combin-
ation that offers acceptable viability, whilst promoting or
maintaining desired cell phenotype. Most papers do not
explain the decisions that led them to the selection of
their chosen media or media combination, despite the
critical role that this factor may play in the outcome of the
study. The media mixture may depend on the ratio of
each cell type used, the sensitivity of cells - one cell type
being potentially more sensitive than another to alteration
of media composition - and the purpose of the study.
The addition of supplements to media is another issue
that has to be considered. Co-culturing cells together
will change the expression profile of each cell type through
paracrine signaling and cell-cell interactions. The endogen-
ous factors secreted by the cells in the microenvironment
may contribute to, or may inhibit, the usual effect of sup-
plements in the medium. For example, Unger et al. showed
that in monoculture of HDMEC, exogenous angiogenic
factors, such as bFGF or VEGF, were required for micro-
vascular formation [68]. However, surprisingly when these
components were added to co-cultures of HDMEC and os-
teoblasts, microcapillary formation did not occur. VEGF
promotes endothelial cell motility, and in this case too
much of this factor may be over stimulating the cells and
destabilizing the network.
There may also be a potential significant difference be-
tween endothelial capillary formation that is driven by ex-
ogenous stimulus in the form of angiogenic supplements
added to culture media versus endogenous angiogenic
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co-culture system. The exogenous supplements are added
as a single dose at the time of media change and their bio-
activity will decrease with time depending on the initial
concentration, stability of the supplement and relative up-
take by the cells. Factors secreted by supporting cells in
co-culture are released more steadily over time but as with
the exogenous supplements the factors will be removed
when the media is changed. Figure 4 shows a visual repre-
sentation of this phenomenon. It is unclear how the differ-
ence between exogenous and endogenous stimulated
capillary formation may influences the structural and
functional aspects of the networks. In the end, the best
way to determine the optimal medium composition
may be experimentally by examining not only the pro-
liferation or viability of each cell type but its impact on
gene expression and cell phenotype.
Seeding technique
There are two main types of seeding parameters re-
searchers can modulate: temporal (seed simultaneously
or sequentially) and spatial (seed on one construct or
multiple constructs).
Seeding the cells in the matrix at the same time allows
for a homogeneous mix of cells throughout the con-
struct (Figure 5A). This is beneficial if cell-cell contact is
important for cell function or if the cell types are natur-
ally co-located with one another in the tissue of interest.
Researchers can also use the same scaffold, but seed the
cells at different times (Figure 5B). In addition to modi-
fying the cell ratio, sequential seeding is beneficial if the
cell proliferation rates differ significantly and there is the
potential that the more proliferative cell type may take
over the construct. Moreover, pre-seeding one cell type
in the scaffold may help direct or bias the overall charac-
teristics of the construct towards a particular phenotype
or trait of interest. For example, Lyer et al. previously
showed that following co-culture of EC, fibroblasts and
cardiomyocytes in matrigel, the cells formed an organoidFigure 4 Representation of the difference between angiogenic factor
use of exogenous supplements to media in a static system. Angiogen
system in a spike dependent manner and reduce over time, whilst endoge
over time.that mimicked cardiac structure and function, but the
EC cells did not organize into capillary structures [131].
However, a separate study from the same group seeded
the EC cells first, followed by fibroblasts 24 hours later,
and cardiomyocytes 48 hours later, which resulted in ex-
tensive cord formation in the end construct [132]. Seed-
ing the EC cells first may have provided the cells with
time to form tubes unimpeded and the addition of fibro-
blasts may have provide the newly formed network with
structural support before the addition of the cardiomyo-
cytes. A difficulty associated with sequential seeding in
the same construct is the requirement to incorporate
cells in a solid scaffold or gel that has already been
made. The construct would need to be either porous, in-
clude hollow microchannels, or require a chemoattract-
ant to encourage cell ingrowth. In the case of Lyer et al.,
the organoids were thin microtissue [132].
Cells can also be spatially separated on different scaf-
folds (Figure 5C-D). As previously mentioned, the prop-
erties of scaffolds can influence the phenotype of the
cells in the tissue-engineered constructs, which may be
problematic if competing characteristics are required. A
way around this problem is to place the cells in separate
scaffolds with optimal properties for each desired cell
trait. These scaffolds can be seeded either simultan-
eously or sequentially but again will depend on the pro-
liferation rates of the cells and the desired cell traits in
the construct. An added advantage of spatially separated
constructs is that they can also be cultured in different
medias before being combined (Figure 5Cii-Dii). This can
overcome some of the possible problems associated with
compromising on shared media conditions. The limitation
of spatially separating the cells is that it allows only
minimal cell-cell contact between the different cell types.
Dynamic systems
Bioreactor systems are commonly used within an in vitro
cell culture system to control oxygen and nutrient diffusion,
alter gene expression and even promote the differentiations supplied by endogenous support cells in co-culture versus the
ic factors from an exogenous source (red) are introduced into the
nous angiogenic factors (blue) are released into the system steadily
Figure 5 Different cell seeding strategies for co-culture systems in tissue engineering. (A) Cells seeded together in the same construct at
the same time point. (B) Cells seeded together in the same construct at different time points. (C) Cells seeded in different constructs at the same
start point and either cultured (i) together or (ii) separately. (D) Cells seeded in different constructs at different time points and either cultured (i)
together or (ii) separately.
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include hypoxic, rotational and perfusion bioreactors [133].
It has been long known that hypoxia can promote
angiogenesis and vascularisation in tissue [134]. An oxy-
gen dependent homeostatic mechanism in the body en-
sures that all cells receive adequate blood supply [135].
When tissues are exposed to a low oxygen environment
they begin to express factors such as hypoxia-inducible
factor 1(HIF-1) which promotes VEGF production [135].
The VEGF then acts on the endothelial cells to promote
cell migration and vascularisation. Researchers can mimic
this cellular response by modulating oxygen tension in a
controlled environment such as a incubator to control ca-
pillary formation in endothelial cells in vitro [136]. In a
co-culture setting, hypoxic conditions can have either a
positive, negative or no effect on the non-endothelial cells
in the culture system. For example, hypoxic conditions
have been shown to stimulate MSC differentiation into
cartilage and endothelial cells, but actively inhibit MSCdifferentiation into osteoblasts [137-139]. Therefore, hyp-
oxic conditions can have unintended consequences on a
co-culture system depending on the end application.
Studies relating to the utilization of rotational bioreac-
tors in co-culture systems have so far shown mixed re-
sults. Xing et al. immobilized scaffolds co-cultured with
bone marrow stromal cells and endothelial cells on sta-
tionary needles in a spinner flask moving in a single direc-
tion on the x-axis [140]. After a week in the bioreactor,
extensive capillary networks formed within the scaffolds.
However, in a study by Liu et al. that co-cultured EPC and
MSC on immobilized scaffolds using a biaxial bioreactor
which was rotating simultaneously on a perpendicular
axes (X and Z), no vessel formation was observed in the
dynamic system, but extensive vessel network formed
under static conditions after a week of culture in vitro
[141]. In this scenario, the bidirectional flow in the biaxial
bioreactor may have eliminated the oxygen gradient that
occurs naturally in gels and scaffolds and promotes
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may be maintained in the static culture and the unidirec-
tional spinner flask.
Perfusion systems can be used to mimic the haemo-
dynamic forces and pressures that occur naturally in the
human body. Fluid flow in a bioreactor can be directed
through the bulk of a construct, however in most cases
it will be directed through hollow microchannels or
pores within the construct, similar to those described in
section 3.1, that have been pre-seeded with endothelial
or perivascular cells. Several studies have shown that
mechanical stimulation under peristaltic flow conditions
can increase the production of ECM proteins, such as
elastin and collagen, and improve the mechanical proper-
ties of the vessel or capillary as measured by burst pressure
and resistance to shear stress [142]. Mechanical stimulation
by perfusion systems is critical in pre-conditioning vascular
constructs prior to implantation.
Conclusion
In vitro pre-vascularization strategies provide researchers
with greater control over the design and outcome of
tissue-engineered constructs. However, with a higher de-
gree of control comes an innumerable range of cell culture
options to choose from. In the case of co-culture systems,
the amount of choices increases exponentially. Examining
the literature, one would not be mistaken in assuming that
no consensus exists on optimal cell culture conditions.
When reviewing the literature, researchers need to separate
out and analyze the different variables in order to make
effective comparison to their own work or other studies in
the literature. This review examined the various important
factors to take into consideration when evaluating co-
culture systems, such as scaffold type, cell source, cell ratio,
medium, seeding technique and bioreactor systems.
There are a variety of cell sources for vascularized tis-
sue constructs; however, endothelial cells are the one cell
type that is ubiquitous in almost all systems. EC are het-
erogeneous in nature and contain a mix of subpopula-
tions. EPC cells hold great promise in the field and have
been shown to enhance proliferative ability, survival rate
and angiogenic potential. Stem cell-derived EC also rep-
resent a viable alternative to directly isolating endothelial
cells and its precursors, however issues including ethical
concerns, source availability and tumourgenicity limit
their application. Other cell types co-cultured with
endothelial cells have also been shown to play both
direct and indirect roles in the development and mat-
uration of capillary networks.
The selection of appropriate scaffolds is also an im-
portant consideration. ECs require a 3D environment,
with adhesion and degradation sites, in order to form
functional tube structures with a lumen. EC capillary
formation is also strongly associated with decreasinghydrogel stiffness. Modifying cell ratios can help prevent
one cell type taking over the construct and/or push a
co-culture system towards a particular desired cell trait.
When optimizing cell culture media, researchers need to
take into account the factors released by both cell types
as it changes the dynamics of the culture. Supplements
that previously supported a cell type in monoculture
may not be required or may even have a detrimental ef-
fect on cells in co-culture. Finally, specialized seeding
techniques and dynamic bioreactors can be used to over-
come barriers in co-culture systems, but the optimal
strategy will depend on the desired outcome.
Balancing all these conditions can be difficult, and
with increasing number of novel biomaterials, cell isola-
tion strategies, media formulations, seeding techniques
and bioreactor systems being developed, the variety of
options available to researchers is only set to continue.
However, it is important for researchers to be able to
identify parameters, understand the interrelationship be-
tween variables and appreciate the knock-on effect that
changing of different conditions can have on a co-
culture system, in order to help them appropriately de-
sign their experiments and achieve the desired research
outcomes.Additional file
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